Enhanced circulation half-life of site-specific PEGylated rhG-CSF: Optimization of PEG molecular weight

Journal of Biotechnology

Volumn 142, Issue 3-4, 2009, Pages 259-266

  Zhai, Yanqin ^a,b   Zhao, Yongjiang ^a,b   Lei, Jiandu ^a   Su, Zhiguo ^a   Ma, Guanghui ^a  

^a INSTITUTE OF PROCESS ENGINEERING   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

Drug bioavailability; Granulocyte colony stimulating factor (G CSF); Serum half life; Site specific PEGylation

Indexed keywords

CLINICAL USE; DRUG BIOAVAILABILITY; GRANULOCYTE COLONY STIMULATING FACTOR (G-CSF); GRANULOCYTE-COLONY STIMULATING FACTOR; IN-VITRO; IN-VIVO; METHOXY; N-TERMINAL; NEUTROPENIA; PRODUCTION COST; PROPIONALDEHYDE; SERUM HALF-LIFE; SITE-SPECIFIC; SITE-SPECIFIC PEGYLATION; THERAPEUTIC EFFICACY; VITRO ACTIVITY;

BIOCHEMISTRY; BODY FLUIDS; ETHYLENE; ETHYLENE GLYCOL; MOTION PICTURE EXPERTS GROUP STANDARDS; POLYETHYLENE OXIDES;

POLYETHYLENE GLYCOLS;

MACROGOL; PROPIONALDEHYDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; CHEMICAL REACTION; CIRCULAR DICHROISM; CONTROLLED STUDY; DOG; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; DRUG PURITY; FINANCIAL MANAGEMENT; IN VITRO STUDY; IN VIVO STUDY; ISOELECTRIC FOCUSING; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; SEPARATION TECHNIQUE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ANIMALS; BIOLOGICAL AVAILABILITY; CHROMATOGRAPHY, GEL; CHROMATOGRAPHY, ION EXCHANGE; CIRCULAR DICHROISM; DOGS; GRANULOCYTE COLONY STIMULATING FACTOR, RECOMBINANT; HALF-LIFE; HUMANS; MALE; MOLECULAR WEIGHT; POLYETHYLENE GLYCOLS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 67650064606     PISSN: 01681656     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbiotec.2009.05.012     Document Type: Article

References (43)

1. Abuchowski A., Kazo G.M., Verhoest Jr. C.R., Van Es T., Kafkewitz D., Nucci M.L., Viau A.T., and Davis F.F. Cancer therapy with chemically modified enzymes. I. Antitumor properties of polyethylene glycol-asparaginase conjugates. Cancer Biochem. Biophys. 7 (1984) 175-186
2. Bailon P., and Berthold W. Polyethylene glycol-conjugated pharmaceutical proteins. Pharm. Sci. Technol. Today 1 (1998) 352-356
3. Bowen S., Tare N., Inoue T., Yamasaki M., Okabe M., Horii I., and Eliason J.F. Relationship between molecular mass and duration of activity of polyethylene glycol conjugated granulocyte colony-stimulating factor mutein. Exp. Hematol. 27 (1999) 425-432
4. Caliceti P., and Veronese F.M. Pharmacokinetic and biodistribution properties of poly(ethylene glycol)-protein conjugates. Adv. Drug Deliv. Rev. 55 (2003) 1261-1277
5. Chi E.Y., Krishnan S., Kendrick B.S., Chang B.S., Carpenter J.F., and Randolph T.W. Roles of conformational stability and colloidal stability in the aggregation of recombinant human granulocyte colony-stimulating factor. Protein Sci. 12 (2003) 903-913
6. DeNardo S.J., Yao Z.S., Lam K.S., Song A.M., Burke P.A., Mirick G.R., Lamborn K.R., O'Donnell R.T., and DeNardo G.L. Effect of molecular size of pegylated peptide on the pharmacokinetics and tumor targeting in lymphoma-bearing mice. Clin. Cancer Res. 9 (2003) 3854S-3864S
7. Edwards C.K., Martin S.W., Seely J., Kinstler O., Buckel S., Bendele A.M., Ellen Cosenza M., Feige U., and Kohno T. Design of PEGylated soluble tumor necrosis factor receptor type I (PEG sTNF-RI) for chronic inflammatory diseases. Adv. Drug Deliv. Rev. 55 (2003) 1315-1336
8. Eldar-Lissai A., Cosler L.E., Culakova E., and Lyman G.H. Economic analysis of prophylactic pegfilgrastim in adult cancer patients receiving chemotherapy. Value Health 11 (2008) 172-179
9. Fee C.J., and Van Alstine J.M. PEG-proteins: reaction engineering and separation issues. Chem. Eng. Sci. 61 (2006) 924-939
10. Fiegl M., Hiddemann W., and Braess J. Use of pegylated recombinant filgrastim (Pegfilgrastim) in patients with acute myeloid leukemia: pharmacokinetics and impact on leukocyte recovery. Leukemia 22 (2008) 1284-1285
11. Foser S., Schacher A., Weyer K.A., Brugger D., Dietel E., Marti S., and Schreitmüller T. Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon α-2a (PEGASYS). Protein Expr. Purif. 30 (2003) 78-87
12. Frampton J.E., and Keating G.M. Spotlight on pegfilgrastim in chemotherapy-induced neutropenial. Biodrugs 19 (2005) 405-407
13. Gaertner H.F., and Offord R.E. Site-specific attachment of functionalized poly(ethylene glycol) to the amino terminus of proteins. Bioconjug. Chem. 7 (1996) 38-44
14. Grace M.J., Lee S., Bradshaw S., Chapman J., Spond J., Cox S., DeLorenzo M., Brassard D., Wylie D., Cannon-Carlson S., Cullen C., Indelicato S., Voloch M., and Bordens R. Site of pegylation and polyethylene glycol molecule size attenuate interferon-alpha antiviral and antiproliferative activities through the JAK/STAT signaling pathway. J. Biol. Chem. 280 (2005) 6327-6336
15. Hao Y., Chen J.H., Wang X.C., Zhu H.W., and Rong Z.G. Effects of site-specific polyethylene glycol modification of recombinant human granulocyte colony-stimulating factor on its biologic activities. Biodrugs 20 (2006) 357-362
16. Harris J.M., and Chess R.B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2 (2003) 214-221
17. Ishiguro H., Kitano T., Yoshibayashi H., Toi M., Ueno T., Yasuda H., Yanagihara K., Garbo C.L., and Fukushima M. Prolonged neutropenia after dose-dense chemotherapy with pegfilgrastim. Ann. Oncol. 19 (2008) 1019-11019
18. Kinstler O.B., Brems D.N., and Lauren S.L. Characterization and stability of N-terminally PEGylated rhG-CSF. Pharm. Res. (1996) 996-1002
19. Kuga T., Komatsua K., Yamasakia M., Sekinea S., Miyajia H., Nishia T., Satoa M., Yokooa Y., Asanob M., Okabeb M., Morimotob M., and Itoh S. Mutagenesis of human granulocyte colony stimulating factor. Biochem. Biophys. Res. Commun. 59 (1989) 103-111
20. Lago S., Nasciben V., and Saggia M.G. Cost-minimization analysis of once-per-cycle fixed-dose administration of pegfilgrastim versus daily filgrastim for the prophylaxis of chemotherapy-induced febrile neutropenia in Brazil. Value Health 10 (2007) A332-A1332
21. Lee B.K., Kwon J.S., Kim H.J., Yamamoto S., and Lee E.K. Solid-phase PEGylation of recombinant interferon alpha-2a for site-specific modification: process performance, characterization, and in vitro bioactivity. Bioconjug. Chem. 18 (2007) 1728-1734
22. Li X.Q., Lei J.D., Su Z.G., and Ma G.H. Comparison of bioactivities of monopegylated rhG-CSF with branched and linear mPEG. Process Biochem. 42 (2007) 1625-1631
23. ®). Curr. Pharm. Des. 10 (2004) 1235-1244
24. Morishita M., and Leonard R.C. Pegfilgrastim: a neutrophil mediated granulocyte colony stimulating factor-expanding uses in cancer chemotherapy. Expert. Opin. Biol. Ther. 8 (2008) 993-1001
25. Na D.H., Youn Y.S., Lee I.B., Park E.J., Park C.J., and Lee K.C. Effect of molecular size of PEGylated recombinant human epidermal growth factor on the biological activity and stability in rat wound tissue. Pharm. Dev. Technol. 11 (2006) 513-519
26. Pasut G., and Veronese F.M. Polymer-drug conjugation, recent achievements and general strategies. Prog. Polym. Sci. 32 (2007) 933-961
27. ® (pegfilgrastim). Adv. Drug Deliv. Rev. 60 (2008) 50-58
28. Russell, N., Mesters, R., Pfreundschuh, M., Boogaerts, M., Johnsen, H., Canizo, M., Barker, P., Quinn, G., Schmitz, N., 2005. Pegfilgrastim (6 mg or 12 mg) mobilizes CD34+cells similarly to filgrastim (5 μg/kg/day) when administered following chemotherapy in patients with non-Hodgkin's lymphoma. Blood 106, 560A-560A.
29. Seely J.E., Buckel S.D., Green P.D., and Richey C.W. Making site-specific PEGylation work. Biopharm. Int. 18 (2005) 30-130
30. Seely J.E., and Richey C.W. Use of ion-exchange chromatography and hydrophobic interaction chromatography in the preparation and recovery of polyethylene glycol-linked proteins. J. Chromatogr. A 908 (2001) 235-241
31. Sherman M.R., Williams L.D., Saifer M.G.P., French J.A., Kwak L.W., and Oppenheim J.J. Conjugation of high-molecular weight poly(ethylene glycol) to cytokines: granulocyte-macrophage colony-stimulating factors as model substrates. In: Harris J.M., and Zalipsky S. (Eds). Poly(ethylene glycol): Chemistry and Biological Applications (1997), American Chemical Society, Washington 155-169
32. Shirafuji N., Asano S., Matsuda S., Watari K., Takaku F., and Nagata S. A new bioassay for human granulocyte colony-stimulating factor (hG-CSF) using murine myeloblastic NFS-60 cells a targets and estimation of its levels in sera from normal healthy-persons and patients with infections and hematological disorders. Exp. Hematol. 17 (1989) 116-119
33. Sierra J., Szer J., Kassis J., Herrmann R., Lazzarino M., Thomas X., Noga S.J., Baker N., Dansey R., and Bosi A. A single dose of pegfilgrastim compared with daily filgrastim for supporting neutrophil recovery in patients treated for low-to-intermediate risk acute myeloid leukemia: results from a randomized, double-blind, phase 2 trial. BMC Cancer 8 (2008) 195-1195
34. Sung L., and Dror Y. Clinical applications of granulocyte-colony stimulating factor. Front. Biosci. 12 (2007) 1988-2002
35. Venkatachalam M.A., and Rennke H.G. The structural and molecular basis of glomerular filtration. Circ. Res. 43 (1978) 337-347
36. Veronese F.M., Mero A., Caboi F., Sergi M., Marongiu C., and Pasutt G. Site-specific pegylation of G-CSF by reversible denaturation. Bioconjug. Chem. 18 (2007) 1824-1830
37. Veronese F.M., and Harris J.M. Peptide and protein PEGylation III: advances in chemistry and clinical applications. Adv. Drug Deliv. Rev. 60 (2008) 1-2
38. Welte K., Gabrilove J., Bronchud M.H., Platzer E., and Morstyn G. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 88 (1996) 1907-1929
39. Yamaoka T., Tabata Y., and Ikada Y. Distribution and tissue uptake of poly(ethylene glycol) with different molecular weights after intravenous administration to mice. J. Pharm. Sci. 83 (1994) 601-606
40. Yamaoka T., Tabata Y., and Ikada Y. Fate of water-soluble polymers administered via different routes. J. Pharm. Sci. 84 (1995) 349-354
41. Yu P.Z., Zheng C.Y., Chen J., Zhang G.F., Liu Y.S., Suo X.Y., Zhang G.C., and Su Z.G. Investigation on PEGylation strategy of recombinant human interleukin-1 receptor antagonist. Bioorg. Med. Chem. 15 (2007) 5396-5405
42. Yun Q., Yang R.E., Chen T., Bi J.X., Ma G.H., and Su Z.G. Reproducible preparation and effective separation of PEGylated recombinant human granulocyte colony-stimulating factor with novel "PEG-pellet" PEGylation mode and ion-exchange chromatography. J. Biotechnol. 118 (2005) 67-74
43. Zhao Y.J., Zhai Y.Q., Ma G.H., and Su Z.G. Kinetic analysis and improvement of the Williamson reaction for the synthesis of poly(ethylene glycol) propionaldehyde. J. Appl. Polym. Sci. Symp. 111 (2009) 1638-1643